Kineta. Inc., is a biotechnology company focused on the development of new, targeted immune modulating drugs. Our progressive business model is aimed at rapid development to benefit patients and investors more quickly than traditional models.
Kineta is developing five drug and vaccine adjuvant programs with a focus on autoimmune diseases, antivirals and chronic pain. All our drugs have unique mechanisms of action and address unmet medical needs in large patient populations.